

antibodies against N⁵-methyl-N⁵-formyl-2,5,6,-triamino-4-hydroxy-pyrimidine, antibodies against N⁷-ethyl guanine, antibodies against O⁶-methyl-2'-deoxyguanosine, antibodies against O⁶-ethyl-2'-deoxyguanosine, antibodies against O⁶-N-butyl-2'-deoxyguanosine, antibodies against O⁶-isopropyl-2'-deoxyguanosine, antibodies against O⁴-methyl-2'-deoxyguanosine or antibodies against O⁴-ethyl-2'-deoxyguanosine, antibodies against methylated DNA, especially against N⁶-methylated adenin.

(2) antibodies directed against envelope proteins or viruses such as for example

- murine leukemia virus, the antibody being preferably directed against envelope proteins gp70 and p15,
- HIV,
- herpes simplex virus, the antibody being preferably directed against glycoprotein B, glycoprotein H, glycoprotein L,
- cytomegalovirus, the antibody being preferably directed against glycoprotein B (gpB),
- adeno-associated virus,
- minute virus of mice,
- antibodies against adeno-associated virus, the antibody being preferably directed against Cap- and Rep-proteins,
- cytomegalovirus, the antibody being preferably directed against glycoprotein B (gpB).—

REMARKS

The purpose of this Supplemental response is to correct a typographical error in the amendment to the specification filed March 11, 2002. Specifically, the Greek symbols associated with "FC- γ FC- ϵ or FC- μ " were inadvertently deleted from the text of

Serial No. 09/288,719

the amendment when filed. Applicants herewith simply wish to ensure that such symbols are, in fact, added to the specification. A marked up copy of the amendment is attached.

CONCLUSION

Applicants assert that entry of the above amendment is proper as it does not add new matter and is solely for purposes of correcting an typographical error. Examination on the merits is awaited.

Respectfully submitted,

May 17, 2002
Date

Patricia D. Granados
Patricia D. Granados
Reg. No. 33,683

HELLER, EHRMAN, WHITE
& McAULIFFE LLP
1666 K Street, N.W.
Suite 300
Washington, DC 20006
Tel: (202) 212-2142
Fax: (202) 212-2020

MARKED UP COPY OF AMENDMENT TO SPECIFICATION

Please delete the following at page 10 between the first and second paragraphs:

[The following fusogenic peptides disclosed in DE 196 49 645.4, are listed on page 10, lines 30-64:

- (1) peptide containing the peptide GLFEALLELLESLWELLLEA (Gottschalk *et al.*, *Gene Ther.* 3: 448 (1996));
- (2) peptide containing the peptide AALAEA[LAEA]₄LAAAGC (Acm) (Wang *et al.*, *Technol. Advances in Vector Syst. For Gene Ther.*, May 6-7, 1996, Coronado, IBC Conference);
- (3) peptide containing the peptide FAGV-VLAGAALGVAAAAQI of the fusion protein of measles-virus (Yeagle *et al.*, *Biochem. Biophys. Acta* 1065, 49 (1991));
- (4) peptide containing the peptide GLFGAIAGFIEGGWWGMIDG of the HA2 proteins of Influenza A (Lueneberg *et al.*, *J. Biol. Chem.* 270, 27606 (1995));
- (5) peptide containing the peptide GLFGAIAGFIENGWEGMIDG GLFGAIAGFIENGWEGMIDG (Burger *et al.*, *Biochem.* 30, 11173 (1991)) or the peptide GLFGAIAGFIE; ALFGAIAGFIE; LFLGAIAGFIE; LLLGAIAGFIE; LILGAIAGFIE; GIFGAIAGFIE; GLLGAIAGFIE; GLFAAIAGFIE; GLFEAIAGFIE; GLFGAMAGFIE; GLFGAIAGLIE or the peptide GLFGAIAGFIV (Steinhauer *et al.*, *J. Virol.* 69, 6643 (1995));
- (6) the peptide GLFEAIAEFIEGGWEGLIEG; and
- (7) the peptide GLLEALAELEGGWEGLLEG (Ishiguro *et al.*, *Biochem.* 32, 9792 (1993)).

The following target cell specific ligands are disclosed in DE 196 49 545.4 and listed on page 3, lines 46 through page 9, line 63, thereof:

- (1) antibody fragments directed against membrane structures of endothelial cells such as, for example, Burrows *et al.* (Pharmac. Ther. 64, 155 (1994), Hughes *et al.* (Cancer Res. 49, 6214 (1989) and Murayama *et al.* (PNAS-USA 87, 5744 (1990)) specially antibodies against VEGF-receptors. (disclosed in DE 196 49 645 A1, p. 5, lines 19-22);

- (2) antibodies or antibody fragments directed against membrane structures of immune cells, such as described in Powelson *et al.*, Biotech. Adv. 11, 725 (1993) or antibodies or antibody fragments that bind with their antigen binding part the FC- γ 1 or FC- γ 2 (Rojanasakul *et al.* Pharm. Res. 11, 1731 (1994), (disclosed in DE 196 49 645 A1, p. 5, lines 50-61);
- (3) antibodies or antibody fragments directed against membrane structures of muscle cells, such as the antibody 10F3, antibody against actin, antibody against angiotensin II receptors or antibodies against receptors of growth factors (disclosed in DE 196 49 645 A1, p. 6, lines 48-56);
- (4) antibodies or antibody fragments directed against membrane structures of tumor cells, such antibodies are described in Sedlacek *et al.*, Contrib. to Oncol. 32, Karger Publisher, Munich (1998) and Contrib. to Oncol. 43, Karger Publisher, Munich (1992) (disclosed in DE 196 49 645 A1, page 9, lines 50-54).

The gene construct-specific ligands disclosed in DE 196 49 645.4 and listed on page 11, line 55 through page 13, line 40 thereof are:

- (1) antibodies directed against epitopes newly introduced into DNA such as antibodies directed against methylated DNA, antibodies against O⁶-ethyl deoxyguanosine, antibodies against N⁵-methyl-N⁵-formyl-2,5,6-triamino-4-hydroxy-pyrimidine, antibodies against N⁷-ethyl guanine, antibodies against O⁶-methyl-2'-deoxyguanosine, antibodies against O⁶-ethyl-2'-deoxyguanosine, antibodies against O⁶-N-butyl-2'-deoxyguanosine, antibodies against O⁶-isopropyl-2'-deoxyguanosine, antibodies against O⁴-methyl-2'-deoxyguanosine or antibodies against O⁴-ethyl-2'-deoxyguanosine, antibodies against methylated DNA, especially against N⁶-methylated adenine.

- (2) antibodies directed against envelope proteins or viruses such as for example
- murine leukemia virus, the antibody being preferably directed against envelope proteins gp70 and p15,
 - HIV,
 - herpes simplex virus, the antibody being preferably directed against glycoprotein B, glycoprotein H, glycoprotein L,
 - cytomegalovirus, the antibody being preferably directed against glycoprotein B (gpB),
 - adeno-associated virus,
 - minute virus of mice,
 - antibodies against adeno-associated virus, the antibody being preferably directed against Cap- and Rep-proteins,
- cytomegalovirus, the antibody being preferably directed against glycoprotein B (gpB).]

Please add the following at page 10 between the first and second paragraphs:

The following fusogenic peptides disclosed in DE 196 49 645.4, are listed on page 10, lines 30-64:

- (1) peptide containing the peptide GLFEALLELLESLWELLLEA (Gottschalk *et al.*, *Gene Ther.* 3: 448 (1996));
- (2) peptide containing the peptide AALAEA[LAEA]₄LAAAGC (Acm) (Wang *et al.*, *Technol. Advances in Vector Syst. For Gene Ther.*, May 6-7, 1996, Coronado, IBC Conference);
- (3) peptide containing the peptide FAGV-VLAGAALGVAAAAQI of the fusion protein of measles-virus (Yeagle *et al.*, *Biochem. Biophys. Acta* 1065, 49 (1991));
- (4) peptide containing the peptide GLFGAIAGFIEGGWWGMIDG of the HA2 proteins of Influenza A (Lueneberg *et al.*, *J. Biol. Chem.* 270, 27606 (1995));
- (5) peptide containing the peptide GLFGAIAGFIENGWEGMIDG GLFGAIAGFIENGWEGMIDG (Burger *et al.*, *Biochem.* 30, 11173 (1991)) or the peptide GLFGAIAGFIE; ALFGAIAGFIE; LFLGAIAGFIE;

- LLLGAIAGFIE; LILGAIAGFIE; GIFGAIAGFIE; GLLGAIAGFIE;
GLFAAIAGFIE; GLFEAIAGFIE; GLFGAMAGFIE; GLFGAIAGLIE or the
peptide GLFGAIAGFIV (Steinhauer *et al.*, *J. Virol.* 69, 6643 (1995));
(6) the peptide GLFEAIAEFIEGGWEGLIEG; and
(7) the peptide GLLEALAELEGGWEGLLEG (Ishiguro *et al.*, *Biochem.* 32, 9792
(1993)).

The following target cell specific ligands are disclosed in DE 196 49 545.4 and
listed on page 3, lines 46 through page 9, line 63, thereof:

- (1) antibody fragments directed against membrane structures of endothelial cells such
as, for example, Burrows *et al.* (Pharmac. Ther. 64, 155 (1994), Hughes *et al.*
(Cancer Res. 49, 6214 (1989) and Murayama *et al.* (PNAS-USA 87, 5744 (1990))
specially antibodies against VEGF-receptors. (disclosed in DE 196 49 645 A1, p. 5,
lines 19-22);
- (2) antibodies or antibody fragments directed against membrane structures of immune
cells, such as described in Powelson *et al.*, Biotech. Adv. 11, 725 (1993) or
antibodies or antibody fragments that bind with their antigen binding part the FC- γ
FC- ϵ or FC- μ Rojanasakul *et al.* Pharm. Res. 11, 1731 (1994), (disclosed in DE 196
49 645 A1, p. 5, lines 50-61);
- (3) antibodies or antibody fragments directed against membrane structures of muscle
cells, such as the antibody 10F3, antibody against actin, antibody against
angiotensin II receptors or antibodies against receptors of growth factors (disclosed
in DE 196 49 645 A1, p. 6, lines 48-56);
- (4) antibodies or antibody fragments directed against membrane structures of tumor
cells, such antibodies are described in Sedlacek *et al.*, Contrib. to Oncol. 32, Karger

Publisher, Munich (1998) and Contrib. to Oncol. 43, Karger Publisher, Munich (1992) (disclosed in DE 196 49 645 A1, page 9, lines 50-54).

The gene construct-specific ligands disclosed in DE 196 49 645.4 and listed on page 11, line 55 through page 13, line 40 thereof are:

(1) antibodies directed against epitopes newly introduced into DNA such as antibodies directed against methylated DNA, antibodies against O⁶-ethyl deoxyguanosine, antibodies against N⁵-methyl-N⁵-formyl-2,5,6,-triamino-4-hydroxy-pyrimidine, antibodies against N⁷-ethyl guanine, antibodies against O⁶-methyl-2'-deoxyguanosine, antibodies against O⁶-ethyl-2'-deoxyguanosine, antibodies against O⁶-N-butyl-2'-deoxyguanosine, antibodies against O⁶-isopropyl-2'-deoxyguanosine, antibodies against O⁴-methyl-2'-deoxyguanosine or antibodies against O⁴-ethyl-2'-deoxyguanosine, antibodies against methylated DNA, especially against N⁶-methylated adenine.

(2) antibodies directed against envelope proteins or viruses such as for example

- murine leukemia virus, the antibody being preferably directed against envelope proteins gp70 and p15,
- HIV,
- herpes simplex virus, the antibody being preferably directed against glycoprotein B, glycoprotein H, glycoprotein L,
- cytomegalovirus, the antibody being preferably directed against glycoprotein B (gpB),
- adeno-associated virus,
- minute virus of mice,

Serial No. 09/288,719

- antibodies against adeno-associated virus, the antibody being preferably directed against Cap- and Rep-proteins,
cytomegalovirus, the antibody being preferably directed against glycoprotein B (gpB).